Tonix Pharmaceuticals CEO Seth Lederman joined Proactive's Natalie Stoberman to discuss the recent publication of the company's Phase 3 study on TNX-102 SL for fibromyalgia management in the American College of Rheumatology.
Lederman said the article outlined how the study's results showed improvements in widespread pain and fatigue, which are significant symptoms of fibromyalgia. He explains that TNX-102 SL, a sublingual tablet taken at bedtime, targets sleep quality to enhance overall fibromyalgia symptoms. With the upcoming confirmatory Phase 3 trial results, Lederman said Tonix aims to file a new drug application for TNX-102 SL.
View source version on newsdirect.com: https://newsdirect.com/news/tonix-pharmaceuticals-fibromyalgia-study-published-in-american-college-of-rheumatology-718541245